Cargando…

Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer

Resistance to chemotherapy is widely recognized as one of the major factors limiting therapeutic efficacy and influences clinical outcomes in patients with cancer. Many studies on various tumor types have focused on combining standard-of-care chemotherapy with immunotherapy. However, for cervical ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heeren, A. Marijne, van Luijk, Iske F., Lakeman, Joost, Pocorni, Noëlle, Kole, Jeroen, de Menezes, Renée X., Kenter, Gemma G., Bosse, Tjalling, de Kroon, Cornelis D., Jordanova, Ekaterina S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851216/ https://www.ncbi.nlm.nih.gov/pubmed/31616965 http://dx.doi.org/10.1007/s00262-019-02412-x

Ejemplares similares

MGL Ligand Expression Is Correlated to Lower Survival and Distant Metastasis in Cervical Squamous Cell and Adenosquamous Carcinoma
por: Sahasrabudhe, Neha M., et al.
Publicado: (2019)

Evidence for a coordinate role of CD14+ antigen-presenting cells and regulatory T cells in conditioning the microenvironment of metastatic lymph nodes from patients with cervical cancer
por: Heeren, Marijne, et al.
Publicado: (2014)

A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment
por: van Luijk, Iske F., et al.
Publicado: (2022)

L1 cell adhesion molecule (L1CAM) is a strong predictor for locoregional recurrences in cervical cancer
por: Schrevel, Marlies, et al.
Publicado: (2017)

Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases
por: Ferns, Debbie M., et al.
Publicado: (2016)

Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix
por: Heeren, A Marijne, et al.
Publicado: (2016)

Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area
por: Heeren, A. Marijne, et al.
Publicado: (2015)

Unlocking the therapeutic potential of primary tumor-draining lymph nodes
por: Rotman, Jossie, et al.
Publicado: (2019)

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer
por: Heeren, A. Marijne, et al.
Publicado: (2018)

Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth
por: Heeren, Anne Marijne, et al.
Publicado: (2021)

High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status
por: Veluchamy, John P., et al.
Publicado: (2016)

Immune Cell Infiltrate in Chronic-Active Antibody-Mediated Rejection
por: Sablik, Kasia A., et al.
Publicado: (2020)

Efficacy of PD-1 blockade in cervical cancer is related to a CD8(+)FoxP3(+)CD25(+) T-cell subset with operational effector functions despite high immune checkpoint levels
por: Heeren, A. M., et al.
Publicado: (2019)

Role of paclitaxel and cisplatin as the neoadjuvant treatment for locally advanced squamous cell carcinoma of the vulva
por: Raspagliesi, Francesco, et al.
Publicado: (2014)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2023)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma
por: Scandurra, Giuseppa, et al.
Publicado: (2015)

Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
por: Dai, Huijuan, et al.
Publicado: (2021)

Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy
por: Kong, Tae-Wook, et al.
Publicado: (2014)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017)

Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2022)

Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients
por: Ezzat, A A, et al.
Publicado: (2004)

Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
por: Ijsselsteijn, Marieke E, et al.
Publicado: (2018)

Correction to: Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study
por: Jiang, Li, et al.
Publicado: (2023)

Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
por: Mendoza-Posada, Daniel, et al.
Publicado: (2007)

Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study
por: Zhou, Liheng, et al.
Publicado: (2017)

Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma
por: Mehta, Akash M., et al.
Publicado: (2007)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma
por: Ottenhof, Sarah Rosanne, et al.
Publicado: (2018)

Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma
por: Fan, Yun, et al.
Publicado: (2016)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
por: Goedegebuure, R.S.A., et al.
Publicado: (2021)

Radiation Recall Dermatitis after Treatment with Paclitaxel and Cisplatin
por: Baek, Seung Woo, et al.
Publicado: (2012)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
por: Stathopoulos, G. P., et al.
Publicado: (2010)

Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases
por: de Muynck, Lysanne D. A. N., et al.
Publicado: (2020)

Neoadjuvant chemotherapy with paclitaxel plus cisplatin before radical surgery for locally advanced cervical cancer during pregnancy: A case series and literature review
por: Huang, Huiqiong, et al.
Publicado: (2021)

Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study
por: Gao, Xing, et al.
Publicado: (2022)

Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma
por: Yamazaki, Haruhiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fj70gdtmb24khgg19rtorpguqh